Calcimedica announces positive topline data from phase 2b carpo trial of auxora™ in acute pancreatitis (ap)

Primary objective of the trial met with statistically significant dose response with up to 43.6% relative reduction (2.1 day improvement) in median time to solid food tolerance versus placebo in hyper-inflamed patients statistically significant dose response with up to 61.7% reduction in severe organ failure in all patients versus placebo  up to 100% reduction in hospital stays longer than 21 days planning end-of-phase 2 meeting with the fda in preparation for a pivotal trial conference call to discuss the carpo topline results scheduled for 8:30 a.m. et today la jolla, calif.
AP Ratings Summary
AP Quant Ranking